Insomnia & Sleep Disorders

Overview
Epidemiology
Pathophysiology
Etiology and Risk Factors
Clinical Presentation
Diagnosis
Treatment
Complications
Prognosis
Prevention
Recent Research and Advances
References & Research
Featured Videos

1. Overview

Insomnia is the most common sleep disorder, characterized by persistent difficulty with sleep initiation, duration, consolidation, or quality that occurs despite adequate opportunity for sleep and results in some form of daytime impairment. The International Classification of Sleep Disorders, Third Edition (ICSD-3) and DSM-5 both recognize Chronic Insomnia Disorder as a distinct condition occurring at least 3 nights per week for at least 3 months, representing a significant departure from earlier conceptualizations that classified insomnia as primarily a symptom of other conditions. This reclassification acknowledges that insomnia frequently develops its own self-perpetuating mechanisms independent of any inciting condition.

Sleep disorders more broadly encompass a wide spectrum of conditions organized by the ICSD-3 into seven major categories: insomnia disorders, sleep-related breathing disorders (including obstructive sleep apnea), central disorders of hypersomnolence (including narcolepsy), circadian rhythm sleep-wake disorders, parasomnias (sleepwalking, night terrors, REM sleep behavior disorder), sleep-related movement disorders (restless legs syndrome, periodic limb movement disorder), and other sleep disorders. This article focuses primarily on chronic insomnia disorder while providing context within the broader sleep disorder landscape.

Insomnia represents a major public health concern, associated with significant economic burden estimated at over $100 billion annually in the United States through direct healthcare costs, lost workplace productivity, and increased accident risk. Chronic insomnia is independently associated with increased risk for major depressive disorder, anxiety disorders, substance use disorders, cardiovascular disease, diabetes, and all-cause mortality. Despite its prevalence and impact, insomnia remains significantly underdiagnosed and undertreated, with many patients receiving suboptimal treatment (primarily sedative-hypnotic medications) rather than evidence-based first-line treatment (Cognitive Behavioral Therapy for Insomnia, CBT-I).

2. Epidemiology

Insomnia symptoms (difficulty falling asleep, staying asleep, or waking too early) are reported by approximately 30-35% of the general adult population. Chronic insomnia disorder, meeting full diagnostic criteria with daytime impairment, has a prevalence of approximately 6-10%. The 12-month incidence of new insomnia is approximately 15-20%, though many cases are transient or episodic.

Insomnia is more prevalent in women than men (approximately 1.4:1 ratio), with the gender gap widening after menopause. Prevalence increases with age, affecting approximately 30-48% of older adults (age 65+), though it is debated whether this reflects true age-related vulnerability or increased burden of comorbid medical and psychiatric conditions. Shift workers experience insomnia at rates of 25-35%, significantly higher than daytime workers.

Obstructive sleep apnea (OSA) affects approximately 10-30% of adults, with prevalence rising sharply with obesity. Restless legs syndrome (RLS) has a prevalence of 5-15% in Western populations. Narcolepsy type 1 (with cataplexy) affects approximately 25-50 per 100,000 individuals, while circadian rhythm sleep-wake disorders (delayed sleep-wake phase disorder, shift work disorder) collectively affect 5-10% of the population.

Insomnia frequently co-occurs with psychiatric conditions: approximately 40-60% of patients with chronic insomnia have a comorbid psychiatric disorder, most commonly depression (40%), anxiety (20%), and substance use disorders (10%). Conversely, insomnia is present in 80-90% of major depression episodes and 50-70% of generalized anxiety disorder cases.

3. Pathophysiology

Hyperarousal Model

The dominant neurobiological model of chronic insomnia centers on the concept of hyperarousal — a state of increased physiological and cognitive activation that persists throughout the 24-hour period, not just at night. Evidence for hyperarousal includes elevated whole-body metabolic rate (measured by 24-hour oxygen consumption), increased heart rate variability reflecting sympathovagal imbalance, elevated high-frequency EEG beta activity during NREM sleep, increased cortisol secretion (particularly in the evening), and enhanced whole-brain glucose metabolism measured by FDG-PET during the transition from waking to sleep. This model explains why insomnia patients often feel "tired but wired" and do not simply experience sleepiness but rather a paradoxical state of fatigue combined with inability to fall asleep.

Neurotransmitter Systems

Sleep and wake are regulated by the dynamic interplay of multiple neurotransmitter systems. Wake-promoting systems include the hypocretin/orexin system (lateral hypothalamus), noradrenergic locus coeruleus, serotonergic dorsal raphe nucleus, histaminergic tuberomammillary nucleus, cholinergic basal forebrain and brainstem nuclei, and dopaminergic ventral tegmental area. Sleep-promoting systems include GABAergic neurons in the ventrolateral preoptic area (VLPO) and median preoptic nucleus, which inhibit wake-promoting centers. In insomnia, the balance between these systems is disrupted, with evidence for reduced GABAergic inhibition (lower brain GABA levels measured by MR spectroscopy) and excessive activation of wake-promoting circuits.

The Two-Process Model and Circadian Dysregulation

Sleep regulation is governed by the interaction of Process S (homeostatic sleep pressure), which accumulates during waking through adenosine buildup, and Process C (circadian drive), regulated by the suprachiasmatic nucleus (SCN) of the hypothalamus. In some insomnia patients, there may be blunted homeostatic sleep drive, misalignment between circadian and homeostatic processes, or attenuated circadian melatonin secretion amplitude. The SCN coordinates circadian rhythms through hormonal signals (melatonin from the pineal gland, cortisol from the adrenals) and neural projections influencing body temperature, alertness, and sleep propensity.

Cognitive and Behavioral Maintaining Mechanisms

The 3P model (Spielman model) provides a cognitive-behavioral framework: Predisposing factors (genetic vulnerability, personality traits like neuroticism, trait hyperarousal) lower the threshold for insomnia; Precipitating factors (stressful events, medical illness, schedule changes) trigger acute insomnia; and Perpetuating factors (maladaptive sleep behaviors and cognitions) maintain chronic insomnia after the precipitant has resolved. Key perpetuating factors include excessive time in bed, irregular sleep schedules, daytime napping, sleep-incompatible activities in bed, catastrophic thinking about sleep loss consequences, sleep effort (trying too hard to sleep), and conditioned arousal (the bed/bedroom becoming associated with wakefulness rather than sleep).

4. Etiology and Risk Factors

Predisposing Factors

Genetic vulnerability — heritability estimated at 31-58%; family studies show 2-3 fold increased risk in first-degree relatives; GWAS studies have identified multiple risk loci near genes involved in stress response and neuronal excitability
Female sex — hormonal factors (estrogen, progesterone fluctuations; menopause) contribute to increased vulnerability
Advancing age — changes in sleep architecture (reduced slow-wave sleep and sleep efficiency), circadian amplitude, and increased comorbidities
Personality traits — neuroticism, perfectionism, rumination tendency, trait anxiety
Hyperarousal trait — constitutional tendency toward heightened physiological and cognitive arousal

Precipitating Factors

Psychosocial stressors — work stress, relationship conflict, bereavement, financial difficulties
Medical illness — pain conditions, respiratory disease, cardiac disease, neurological disorders
Psychiatric conditions — depression, anxiety, PTSD, bipolar disorder (often bidirectional relationship)
Substance use — caffeine, alcohol, nicotine, stimulant medications, opioid withdrawal
Schedule disruption — jet lag, shift work, irregular sleep-wake schedules
Environmental factors — noise, light, uncomfortable temperature, bed partner disturbance

Perpetuating Factors

Spending excessive time in bed — weakens the association between bed and sleep
Irregular sleep-wake schedule — disrupts circadian regulation
Daytime napping — reduces homeostatic sleep drive
Sleep-related worry and anxiety — catastrophizing about consequences of poor sleep
Compensatory behaviors — going to bed early, sleeping late, canceling activities after poor sleep
Conditioned hyperarousal — the bedroom becomes a cue for wakefulness rather than sleep
Clock-watching — monitoring time increases sleep anxiety and frustration

Medications and Substances Contributing to Insomnia

Stimulants: caffeine (half-life 5-7 hours), amphetamines, methylphenidate, modafinil
Antidepressants: SSRIs (fluoxetine, sertraline), SNRIs, bupropion, MAOIs
Cardiovascular: beta-blockers, alpha-blockers, diuretics
Respiratory: theophylline, oral corticosteroids, pseudoephedrine
Other: thyroid hormones, nicotine, alcohol (causes sleep fragmentation despite initial sedation)

5. Clinical Presentation

Chronic Insomnia Disorder

Patients report one or more of the following:

Sleep onset insomnia — difficulty falling asleep; typically defined as sleep onset latency (SOL) >30 minutes
Sleep maintenance insomnia — difficulty staying asleep; frequent or prolonged awakenings; wake after sleep onset (WASO) >30 minutes
Early morning awakening — waking earlier than desired and inability to return to sleep
Daytime consequences: fatigue, daytime sleepiness, difficulty concentrating, mood disturbance (irritability, dysphoria), reduced motivation, impaired social/occupational functioning, increased errors/accidents

Obstructive Sleep Apnea

Loud, irregular snoring with witnessed breathing pauses (apneas)
Excessive daytime sleepiness (Epworth Sleepiness Scale >10)
Morning headaches, dry mouth, sore throat
Nocturia, nocturnal gasping/choking episodes
Risk factors: obesity (BMI >30), male sex, age >50, neck circumference >17 inches (men) or >16 inches (women), retrognathia, macroglossia
Consequences: hypertension, atrial fibrillation, stroke, motor vehicle accidents

Restless Legs Syndrome

Irresistible urge to move the legs, usually accompanied by uncomfortable sensations (crawling, tingling, aching, throbbing)
Symptoms worse at rest and in the evening/night
Symptoms relieved by movement (walking, stretching)
Often associated with periodic limb movements of sleep (PLMS)
Associated with: iron deficiency (serum ferritin <75 ng/mL), pregnancy, end-stage renal disease, peripheral neuropathy, dopaminergic medication use

Circadian Rhythm Sleep-Wake Disorders

Delayed Sleep-Wake Phase Disorder (DSWPD) — preferred sleep time shifted 2+ hours later than conventional times; most common in adolescents and young adults; prevalence 7-16% in this age group
Advanced Sleep-Wake Phase Disorder (ASWPD) — sleep onset and wake times 2+ hours earlier than desired; more common in older adults
Shift Work Disorder — insomnia and/or excessive sleepiness related to work schedules during the normal sleep period
Non-24-Hour Sleep-Wake Rhythm Disorder — most common in totally blind individuals; circadian rhythm free-runs on a period slightly longer than 24 hours

Narcolepsy

Excessive daytime sleepiness — irresistible sleep attacks, most prominent in monotonous situations
Cataplexy (Type 1 only) — sudden, brief episodes of bilateral muscle weakness triggered by emotions (laughter, surprise, anger); ranges from subtle jaw dropping to complete postural collapse
Hypnagogic/hypnopompic hallucinations — vivid, often frightening visual/auditory hallucinations at sleep onset or upon waking
Sleep paralysis — temporary inability to move upon waking or falling asleep
Disrupted nighttime sleep — fragmented sleep architecture despite excessive daytime sleepiness
Pathophysiology: autoimmune destruction of hypocretin/orexin-producing neurons in the lateral hypothalamus; CSF hypocretin-1 levels <110 pg/mL are diagnostic for narcolepsy type 1

6. Diagnosis

Clinical Assessment

Detailed sleep history — bedtime, wake time, sleep onset latency, number and duration of awakenings, total sleep time, napping patterns, bedroom environment, pre-sleep behaviors
Sleep diary — 1-2 week prospective record of daily sleep patterns; the most important diagnostic tool for chronic insomnia; captures night-to-night variability
Medical and psychiatric history — screen for comorbid conditions that may cause or worsen insomnia
Medication and substance review — caffeine, alcohol, prescription and OTC medications affecting sleep
Bed partner interview — for witnessed apneas, snoring, leg movements, parasomnias

Screening Instruments

Insomnia Severity Index (ISI) — 7-item self-report; scores 0-28; 0-7 no insomnia, 8-14 subthreshold, 15-21 moderate, 22-28 severe; validated cutoff of ≥10 for clinical insomnia
Pittsburgh Sleep Quality Index (PSQI) — 19-item measure of sleep quality over the past month; global score >5 indicates poor sleep quality
Epworth Sleepiness Scale (ESS) — 8-item measure of daytime sleepiness; score >10 suggests excessive sleepiness; important for differentiating sleepiness (sleep apnea, narcolepsy) from fatigue (insomnia)
STOP-BANG Questionnaire — 8-item screen for obstructive sleep apnea risk; score ≥3 indicates intermediate-high risk

Objective Sleep Testing

Polysomnography (PSG) — overnight laboratory-based sleep study recording EEG, EOG, EMG, airflow, respiratory effort, pulse oximetry, ECG, and limb movements; gold standard for diagnosing sleep apnea, periodic limb movement disorder, narcolepsy, and parasomnias; not routinely indicated for uncomplicated insomnia
Home sleep apnea testing (HSAT) — portable monitoring for suspected OSA; records airflow, respiratory effort, and oximetry; appropriate for patients with high pretest probability of moderate-severe OSA without significant comorbidities
Multiple Sleep Latency Test (MSLT) — daytime nap study for narcolepsy diagnosis; mean sleep latency <8 minutes with ≥2 sleep-onset REM periods (SOREMPs) supports narcolepsy diagnosis
Actigraphy — wrist-worn accelerometer measuring rest-activity patterns over 1-2 weeks; useful for assessing circadian rhythm disorders and sleep-wake patterns in natural settings

DSM-5 Diagnostic Criteria for Insomnia Disorder

A: Predominant complaint of dissatisfaction with sleep quantity or quality associated with difficulty initiating sleep, maintaining sleep, or early morning awakening
B: Sleep disturbance causes clinically significant distress or impairment
C: Difficulty occurs despite adequate opportunity for sleep
D: At least 3 nights per week
E: Duration at least 3 months
F: Not better explained by another sleep-wake disorder
G: Not attributable to substance effects
H: Coexisting mental/medical conditions do not adequately explain the insomnia

7. Treatment

First-Line: Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I is recommended as the first-line treatment for chronic insomnia by the American College of Physicians, American Academy of Sleep Medicine, European Sleep Research Society, and British Association for Psychopharmacology. CBT-I produces improvements comparable to medication in the short term and superior outcomes in the long term, with effects maintained for years after treatment ends. Typically delivered in 4-8 sessions over 6-8 weeks. Components include:

Sleep restriction therapy — limiting time in bed to match actual sleep time (creating mild sleep deprivation that consolidates sleep and strengthens sleep drive); gradually increasing as sleep efficiency improves above 85%
Stimulus control therapy — reassociating the bed/bedroom with sleep: go to bed only when sleepy; leave bed if unable to sleep within ~20 minutes; use bed only for sleep and sex; wake at the same time daily regardless of sleep
Cognitive restructuring — identifying and challenging maladaptive beliefs about sleep (e.g., "I need 8 hours or I can't function," "If I don't sleep tonight, something terrible will happen")
Sleep hygiene education — regular schedule, comfortable environment, limiting caffeine/alcohol, reducing screen time before bed (note: sleep hygiene alone is insufficient as monotherapy)
Relaxation training — progressive muscle relaxation, diaphragmatic breathing, mindfulness meditation

CBT-I delivery formats:

Individual therapy (4-8 sessions) — most studied format
Group therapy (6-8 sessions) — comparably effective; more cost-efficient
Digital CBT-I (dCBT-I) — online programs (Somryst/Pear Therapeutics — FDA-authorized prescription digital therapeutic, Sleepio, CBT-i Coach); comparable efficacy to in-person delivery in multiple RCTs
Brief behavioral treatment for insomnia (BBTI) — condensed 1-4 session version focusing on sleep restriction and stimulus control; suitable for primary care delivery

Pharmacotherapy

Medications are considered second-line or adjunctive to CBT-I, used when CBT-I is unavailable, insufficient, or for short-term symptom management:

Orexin receptor antagonists (DORAs):

Suvorexant (Belsomra) — 10-20 mg at bedtime; blocks orexin-A and orexin-B receptors; improves sleep onset and maintenance; generally well-tolerated; most common side effect is next-day somnolence
Lemborexant (Dayvigo) — 5-10 mg at bedtime; similar mechanism to suvorexant; may have less next-day residual effects

Melatonin receptor agonists:

Ramelteon (Rozerem) — 8 mg at bedtime; selective MT1/MT2 receptor agonist; no abuse potential; primarily improves sleep onset latency; no evidence of dependence or rebound insomnia

Benzodiazepine receptor agonists ("Z-drugs"):

Zolpidem (Ambien) — 5-10 mg (women 5 mg recommended); short half-life (2-3 hours); immediate and extended-release formulations available; FDA warnings about complex sleep behaviors (sleepwalking, sleep-driving)
Eszopiclone (Lunesta) — 1-3 mg at bedtime; longer duration; evidence for sustained efficacy over 6 months
Zaleplon (Sonata) — 5-10 mg; ultrashort half-life (1 hour); useful for sleep-onset insomnia or middle-of-the-night dosing

Low-dose doxepin:

Doxepin (Silenor) — 3-6 mg at bedtime; selective H1 histamine antagonist at low doses; FDA-approved for sleep maintenance insomnia; no evidence of dependence; particularly useful in older adults

Medications used off-label (limited or mixed evidence):

Trazodone — 25-100 mg at bedtime; the most commonly prescribed medication for insomnia despite limited RCT evidence for this indication; serotonin antagonist and reuptake inhibitor with antihistaminic properties
Gabapentin — 100-600 mg at bedtime; may be particularly useful for insomnia comorbid with pain or restless legs syndrome
Melatonin — 0.5-5 mg; most useful for circadian rhythm disorders and jet lag; modest evidence for chronic insomnia; should be taken 1-2 hours before desired sleep time

Medications to avoid or use with caution: Traditional benzodiazepines (diazepam, lorazepam, clonazepam) — effective but carry significant risks of tolerance, dependence, withdrawal, cognitive impairment, falls (especially in older adults), and rebound insomnia. The American Geriatrics Society Beers Criteria recommend avoiding all benzodiazepines and Z-drugs in adults ≥65 years.

Treatment of Other Sleep Disorders

OSA: Continuous positive airway pressure (CPAP) is the gold standard; alternatives include oral appliance therapy and hypoglossal nerve stimulation (Inspire device)
Restless Legs Syndrome: Iron supplementation (if ferritin <75 ng/mL), gabapentinoids (first-line: gabapentin enacarbil 600 mg, pregabalin 75-300 mg), low-dose dopamine agonists (pramipexole 0.125-0.5 mg, ropinirole 0.25-4 mg) as second-line due to augmentation risk
Narcolepsy: Daytime sleepiness treated with modafinil (200-400 mg), solriamfetol (75-150 mg), or pitolisant (17.8-35.6 mg); cataplexy treated with sodium oxybate (Xyrem, 4.5-9 g/night in divided doses), low-dose oxybate (Xywav), or antidepressants (venlafaxine, fluoxetine)
Circadian rhythm disorders: Properly timed bright light therapy, melatonin administration, and chronotherapy (gradual schedule shifts)

8. Complications

Major depressive disorder — chronic insomnia confers a 2-3 fold increased risk of developing depression; bidirectional relationship with depression both causing and resulting from insomnia
Anxiety disorders — insomnia increases risk of incident anxiety by approximately 2-fold
Cardiovascular disease — insomnia is independently associated with 45% increased risk of coronary heart disease and 15% increased stroke risk in meta-analyses
Hypertension — short sleep duration (<5-6 hours) associated with 20-32% increased risk of hypertension
Type 2 diabetes — sleep restriction impairs glucose tolerance and insulin sensitivity; chronic insomnia increases diabetes risk by approximately 40%
Obesity — short sleep alters appetite-regulating hormones (increased ghrelin, decreased leptin), promoting weight gain
Immune dysfunction — sleep restriction reduces natural killer cell activity and increases susceptibility to infection
Cognitive impairment — impaired attention, working memory, executive function, and decision-making; chronic sleep loss may accelerate cognitive decline and increase Alzheimer disease risk through impaired glymphatic clearance of amyloid-beta
Accidents and injuries — drowsy driving causes approximately 100,000 motor vehicle crashes annually in the US; workplace accidents and errors increase with sleep deprivation
Substance use disorders — insomnia patients are more likely to use alcohol, cannabis, or sedatives as sleep aids, increasing dependence risk
Reduced quality of life — comparable to or greater than the impact of chronic conditions like diabetes and congestive heart failure on quality of life measures

9. Prognosis

Acute insomnia (triggered by identifiable stressors) typically resolves within days to weeks as the stressor abates or adaptation occurs. However, approximately 40-70% of acute insomnia transitions to chronic insomnia, typically through the development of maladaptive sleep behaviors and cognitions (perpetuating factors in the Spielman model). Risk factors for chronicity include female sex, older age, hyperarousal tendency, and psychiatric comorbidity.

Without treatment, chronic insomnia follows a persistent course in the majority of cases. Natural history studies show that approximately 40-50% of individuals with chronic insomnia continue to meet diagnostic criteria 3-5 years later, and 27% remain persistently affected at 20-year follow-up. This chronicity underscores the importance of early, evidence-based intervention.

With CBT-I treatment, approximately 70-80% of patients show clinically significant improvement, and 40-50% achieve remission (ISI <8). Critically, these gains are maintained at 1-2 year follow-up without ongoing treatment. By contrast, pharmacotherapy often produces rapid but temporary improvement, with symptom recurrence common upon discontinuation and risks of tolerance with prolonged use (particularly for benzodiazepines and Z-drugs). The combination of pharmacotherapy with CBT-I may be useful for short-term management, with the goal of tapering medication once CBT-I skills are established.

10. Prevention

Maintain consistent sleep-wake schedule — go to bed and wake at the same time daily, including weekends; the single most important sleep hygiene behavior
Optimize sleep environment — dark (use blackout curtains or sleep mask), quiet (use earplugs or white noise), cool (60-67F / 15-19C), comfortable mattress and pillows
Limit caffeine intake — avoid caffeine within 6-8 hours of bedtime; individual sensitivity varies; total daily intake should ideally not exceed 400 mg
Limit alcohol — while initially sedating, alcohol disrupts sleep architecture (suppresses REM, causes rebound awakenings in the second half of the night); avoid within 3-4 hours of bedtime
Regular physical activity — at least 150 minutes per week of moderate exercise; improves sleep quality with effect sizes comparable to benzodiazepines; avoid vigorous exercise within 1-2 hours of bedtime
Manage light exposure — bright light exposure in the morning (to reinforce circadian rhythm); reduce blue light exposure (screens, LEDs) in the evening; consider blue-light filtering glasses or night mode on devices
Stress management — address anticipatory worry before bedtime through scheduled worry time, journaling, or relaxation techniques
Screen for sleep disorders in primary care settings, particularly in patients with depression, anxiety, chronic pain, or cardiovascular risk factors
Early intervention for acute insomnia — brief behavioral interventions (1-2 sessions of stimulus control and sleep restriction) can prevent the transition from acute to chronic insomnia
Workplace policies — adequate rest periods for shift workers, drowsy driving awareness programs, nap-friendly workplace policies

11. Recent Research and Advances

Orexin receptor antagonists (DORAs) represent the most significant pharmacological advance in insomnia treatment in recent years. Unlike traditional sedative-hypnotics that broadly enhance GABAergic inhibition, DORAs selectively block the wake-promoting orexin/hypocretin system, producing sleep that more closely resembles natural sleep architecture. Long-term studies of suvorexant and lemborexant demonstrate sustained efficacy without evidence of tolerance or rebound insomnia, and lower abuse potential compared to benzodiazepine receptor agonists. A newer DORA, daridorexant (Quviviq), approved in 2022, has shown improved next-day functioning in addition to sleep benefits.

Digital CBT-I (dCBT-I) has been validated as an effective treatment delivery method, addressing the critical shortage of trained CBT-I providers. Somryst (now Pear-004) became the first FDA-authorized prescription digital therapeutic for insomnia. Large-scale randomized trials of platforms like Sleepio have demonstrated efficacy in reducing insomnia severity, depression, and anxiety with effect sizes comparable to face-to-face CBT-I. Integration of dCBT-I into primary care and stepped-care models is advancing rapidly.

Sleep and Alzheimer's disease research has revealed critical connections. The glymphatic system — a brain waste clearance pathway most active during deep sleep — clears amyloid-beta and tau proteins implicated in Alzheimer pathology. Chronic sleep disruption impairs glymphatic function and accelerates amyloid accumulation. This has generated interest in treating insomnia and sleep apnea as potential strategies for Alzheimer's disease prevention, with clinical trials underway examining whether improving sleep quality can slow cognitive decline.

Wearable technology and consumer sleep trackers (Apple Watch, Oura Ring, WHOOP, Fitbit) are increasingly capable of estimating sleep stages, though accuracy remains variable compared to polysomnography. These devices are being integrated into clinical research and may enable large-scale population-level sleep monitoring. However, clinicians must manage orthosomnia — a phenomenon where excessive reliance on sleep tracker data paradoxically worsens insomnia through increased sleep-related monitoring and anxiety.

Precision medicine approaches are emerging, with research identifying insomnia subtypes based on EEG biomarkers, circadian chronotype, and comorbidity profiles that may predict differential response to CBT-I versus pharmacotherapy. Machine learning algorithms applied to wearable device data and electronic health records may enable personalized treatment recommendations in the future.

12. References & Research

Historical Background

Sleep medicine as a clinical discipline is remarkably young. Nathaniel Kleitman, considered the father of modern sleep research, established the first sleep laboratory at the University of Chicago in the 1920s and co-discovered REM sleep in 1953 with his graduate student Eugene Aserinsky. William Dement, a student of Kleitman, founded the first clinical sleep disorders center at Stanford in 1970 and helped establish sleep medicine as a medical specialty. The behavioral model of insomnia was formalized by Arthur Spielman with his 3P model (predisposing, precipitating, perpetuating factors) in 1987. Charles Morin and Jack Edinger developed and validated Cognitive Behavioral Therapy for Insomnia (CBT-I) through seminal randomized controlled trials in the 1990s-2000s. The discovery of orexin/hypocretin by Masashi Yanagisawa and Luis de Lecea in 1998 led to the development of DORA medications and earned Yanagisawa the 2024 Breakthrough Prize in Life Sciences.

Key Research Papers

Morin CM, LeBlanc M, Daley M, et al. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med. 2006;7(2):123-130. DOI: 10.1016/j.sleep.2005.08.008
Qaseem A, Kansagara D, Forciea MA, et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125-133. DOI: 10.7326/M15-2175
Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(2):255-262. DOI: 10.5664/jcsm.8986
Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). Sleep. 2006;29(11):1398-1414. DOI: 10.1093/sleep/29.11.1398
Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am. 1987;10(4):541-553. DOI: 10.1016/S0193-953X(18)30532-X
Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev. 2010;14(1):9-15. DOI: 10.1016/j.smrv.2009.05.002
Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377. DOI: 10.1126/science.1241224
Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136-148. DOI: 10.1016/j.biopsych.2014.10.003
Espie CA, Emsley R, Kyle SD, et al. Effect of digital cognitive behavioral therapy for insomnia on health, psychological well-being, and sleep-related quality of life: a randomized clinical trial. JAMA Psychiatry. 2019;76(1):21-30. DOI: 10.1001/jamapsychiatry.2018.2745
Irwin MR, Olmstead R, Carroll JE. Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biol Psychiatry. 2016;80(1):40-52. DOI: 10.1016/j.biopsych.2015.05.014
Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675-700. DOI: 10.1111/jsr.12594
Vgontzas AN, Liao D, Bixler EO, et al. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32(4):491-497. DOI: 10.1093/sleep/32.4.491
Sakurai T. The role of orexin in motivated behaviours. Nat Rev Neurosci. 2014;15(11):719-731. DOI: 10.1038/nrn3837
Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135(1-3):10-19. DOI: 10.1016/j.jad.2011.01.011
Morin CM, Vallieres A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA. 2009;301(19):2005-2015. DOI: 10.1001/jama.2009.682